Welcome to our dedicated page for CRY news (Ticker: CRY), a resource for investors and traders seeking the latest updates and insights on CRY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRY's position in the market.
CryoLife, a prominent company in cardiac and vascular surgery, announced its participation in the 18th Annual Morgan Stanley Global Healthcare Conference on September 16, 2020. The company's management will host a virtual fireside chat at 11:00 a.m. ET, accessible via their website.
As a leader in aortic disease treatments, CryoLife operates in over 100 countries worldwide, offering innovative medical devices and implantable tissues for surgical procedures.
CryoLife has announced the acquisition of Ascyrus Medical for up to $200 million, including an upfront payment of $80 million. This strategic move enhances CryoLife's position in the aortic repair market by adding the Ascyrus Medical Dissection Stent (AMDS), the world's first aortic arch remodeling device for treating acute Type A aortic dissections. The acquisition opens access to an estimated $540 million global market and is expected to drive high single-digit revenue growth starting in 2021, alongside anticipated non-GAAP earnings growth.
CryoLife, Inc. (NYSE: CRY) has announced its participation in two virtual investor conferences. The first event is the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, featuring a fireside chat at 11:00 a.m. ET. Investors can access the live webcast on CryoLife's website.
The second event is the 5th Annual Needham Virtual Med Tech 1x1 Conference on August 17, 2020, with no webcast available. CryoLife specializes in medical devices and tissues for cardiac and vascular surgeries, serving over 100 countries worldwide.
CryoLife reported total revenues of $53.8 million for Q2 2020, a 24% decline from Q2 2019. This decrease reflects the impact of the COVID-19 pandemic on surgical procedures. The company also incurred a net loss of $3.7 million or ($0.10) per diluted share, contrasting with a net income of $2.8 million or $0.07 per share in the previous year. Despite these challenges, CryoLife completed a $100 million convertible debt financing for corporate purposes and initiated enrollment in the PROACT Xa clinical trial.
CryoLife (NYSE: CRY) announced the release date for its second-quarter financial results on July 30, 2020, after market close. A teleconference will be held at 4:30 p.m. ET to discuss the results, led by Chairman and CEO Pat Mackin. Investors can access the conference call by dialing 201-689-8261. A replay will be available from July 30 through August 6, 2020. For more information, visit www.cryolife.com.
CryoLife (NYSE: CRY) announced on June 19, 2020, the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 in a private placement.
The sale is set to close on June 23, 2020. The initial purchaser has the option to buy an additional $15 million in notes. Estimated net proceeds reach approximately $96.5 million, potentially rising to $111.1 million if additional notes are purchased. Funds will primarily cover general corporate purposes, including repaying around $30 million under its revolving credit facility.
CryoLife, Inc. (NYSE: CRY) announced plans to offer up to $100 million in convertible senior notes due 2025, targeting qualified institutional buyers. The offering may include an additional $15 million if the initial purchasers exercise their option. Proceeds are intended for general corporate purposes, primarily to repay approximately $30 million from a revolving credit facility. The notes will be senior unsecured obligations, with semiannual interest payments, and can be converted into cash, shares, or a combination. The offering will be made under securities regulations.